Skip to main content

Erratum to: Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma

Erratum

Following publication of this work [1] the authors noticed a mistake within the article’s competing interests section. The correct competing interests section is provided below.

Reference

  1. 1.

    Okuma Y, Hosomi Y, Miyamoto S, Shibuya M, Okamura T, Hishima T. Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma. BMC Cancer. 2016;16:156. doi:10.1186/s12885-016-2159-7.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Yusuke Okuma.

Additional information

Competing interests

The authors declare that they have no competing interests. This study is supported by the grant for the Clinical Research of Tokyo Metropolitan Hospital and Taiho Pharmaceutical Inc. who analyzed the thymidine synthase, thymidine phosphorylase, orotate phosphoribosyltransferase, and dihydropyrimidine dehydrogenase using RT-PCR.

The online version of the original article can be found under doi:10.1186/s12885-016-2159-7.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Okuma, Y., Hosomi, Y., Miyamoto, S. et al. Erratum to: Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma. BMC Cancer 16, 272 (2016). https://doi.org/10.1186/s12885-016-2309-y

Download citation